Bajorin, Dean F.

Publications

Sort by

Co-Author Network

selected publications

A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer. 2020 Academic Article GET IT
Times cited: 10
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European urology. 2020 Academic Article GET IT
Times cited: 16
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 8
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. The American journal of surgical pathology. 2019 Academic Article GET IT
Times cited: 50
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 16
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 252
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 290
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 83
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 94
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell reports. 2018 Academic Article GET IT
Times cited: 55
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 82
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 343
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 67
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Academic Article GET IT
Times cited: 289
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS medicine. 2017 Academic Article GET IT
Times cited: 209
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 2217
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 1423
Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology. 2016 Academic Article GET IT
Times cited: 8
Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. The Journal of urology. 2016 Academic Article GET IT
Times cited: 6
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 121
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016 Academic Article GET IT
Times cited: 46
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 29
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 135
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clinical genitourinary cancer. 2016 Academic Article GET IT
Times cited: 4
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 2708
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature genetics. 2016 Academic Article GET IT
Times cited: 118
Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human molecular genetics. 2016 Review GET IT
Times cited: 30
Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. International journal of radiation oncology, biology, physics. 2015 Academic Article GET IT
Times cited: 60
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer. 2015 Academic Article GET IT
Times cited: 25
Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 5
Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 145
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. The Journal of urology. 2015 Academic Article GET IT
Times cited: 42
Genomic Characterization of Upper Tract Urothelial Carcinoma. European urology. 2015 Academic Article GET IT
Times cited: 165
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 7
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The oncologist. 2015 Academic Article GET IT
Times cited: 36
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. Hematology/oncology clinics of North America. 2014 Review GET IT
Times cited: 19
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European journal of cancer (Oxford, England : 1990). 2014 Academic Article GET IT
Times cited: 92
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urologic oncology. 2014 Review GET IT
Times cited: 22
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 2
Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 16
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 438
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. European urology. 2014 Academic Article GET IT
Times cited: 110
Reply by the authors. Urology. 2014 Letter GET IT
Times cited: 2
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014 Academic Article GET IT
Times cited: 97
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clinical genitourinary cancer. 2014 Review GET IT
Times cited: 12
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 10
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urologic oncology. 2014 Academic Article GET IT
Times cited: 41
Take care of yourself: we need you. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Editorial Article GET IT
Times cited: 2
Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 38
Highlights from the first symposium on upper tract urothelial carcinoma. Urologic oncology. 2014 Review GET IT
Times cited: 14
Access to chemotherapy services by availability of local and visiting oncologists. Journal of oncology practice. 2014 Academic Article GET IT
Times cited: 40
Enhancing the American Society of Clinical Oncology workforce information system with geographic distribution of oncologists and comparison of data sources for the number of practicing oncologists. Journal of oncology practice. 2014 Academic Article GET IT
Times cited: 49
Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. Journal of oncology practice. 2014 Academic Article GET IT
Times cited: 156
Where do patients with cancer in Iowa receive radiation therapy?. Journal of oncology practice. 2014 Academic Article GET IT
Times cited: 24
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2013 Conference Paper GET IT
Times cited: 51
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 9
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 240
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. World journal of urology. 2013 Academic Article GET IT
Times cited: 22
Phase II study of everolimus in metastatic urothelial cancer. BJU international. 2013 Academic Article GET IT
Times cited: 144
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 73
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 86
Tracking the workforce: the American Society of Clinical Oncology workforce information system. Journal of oncology practice. 2013 Academic Article GET IT
Times cited: 44
Who does not receive treatment for cancer?. Journal of oncology practice. 2013 Academic Article GET IT
Times cited: 33
Genome sequencing identifies a basis for everolimus sensitivity. Science (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 578
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. European urology. 2012 Conference Paper GET IT
Times cited: 143
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012 Academic Article GET IT
Times cited: 22
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urologic oncology. 2012 Review GET IT
Times cited: 30
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. Urology. 2011 Academic Article GET IT
Times cited: 16
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology. 2011 Academic Article GET IT
Times cited: 11
The study of collaborative practice arrangements: where do we go from here?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 8
Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 6
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2011 Academic Article GET IT
Times cited: 51
Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clinical genitourinary cancer. 2011 Academic Article GET IT
Times cited: 3
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Therapeutic advances in urology. 2011 Academic Article GET IT
Times cited: 19
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. European urology. 2011 Academic Article GET IT
Times cited: 17
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Review GET IT
Times cited: 414
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. The Journal of pathology. 2011 Academic Article GET IT
Times cited: 71
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 27
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. Urology. 2011 Academic Article GET IT
Times cited: 11
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. BJU international. 2011 Academic Article GET IT
Times cited: 12
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. Urology. 2010 Academic Article GET IT
Times cited: 12
Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert review of anticancer therapy. 2010 Review GET IT
Times cited: 12
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer. 2010 Academic Article GET IT
Times cited: 24
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU international. 2010 Academic Article GET IT
Times cited: 37
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 135
False elevation of human chorionic gonadotropin in a patient with testicular cancer. 2010 GET IT
Times cited: 14
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Academic Article GET IT
Times cited: 40
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 176
Phase II study of sunitinib in patients with metastatic urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 162
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer. 2009 Academic Article GET IT
Times cited: 13
Bladder cancer: narrowing the gap between evidence and practice. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 44
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 7
Clinical states model for biomarkers in bladder cancer. Future oncology (London, England). 2009 Review GET IT
Times cited: 10
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 37
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 106
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Academic Article GET IT
Times cited: 219
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU international. 2008 Review GET IT
Times cited: 19
Detection of circulating tumor cells in patients with urothelial cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 80
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 16
Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer. 2008 Review GET IT
Times cited: 64
Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. Nature clinical practice. Urology. 2008 Review GET IT
Times cited: 12
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer. 2008 Academic Article GET IT
Times cited: 19
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 44
Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008 Academic Article GET IT
Times cited: 56
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 70
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 98
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 74
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. Journal of translational medicine. 2007 Academic Article GET IT
Times cited: 178
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU international. 2007 Academic Article GET IT
Times cited: 54
The graying of testis cancer patients: what have we learned?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Editorial Article GET IT
Times cited: 11
The evolution of bladder cancer treatment: improvements in clinical management, enhanced clinical outcomes, and targeting newly identified molecular alterations. Seminars in oncology. 2007 Editorial Article GET IT
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 411
Defining optimal therapy for muscle invasive bladder cancer. The Journal of urology. 2007 Review GET IT
Times cited: 180
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer. 2007 Academic Article GET IT
Times cited: 50
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007 Academic Article GET IT
Times cited: 60
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 300
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 108
Advances in urologic oncology: results progress from successful interdisciplinary research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Article GET IT
Times cited: 1
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Investigational new drugs. 2006 Academic Article GET IT
Times cited: 107
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 32
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 74
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 377
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 151
Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Review GET IT
Times cited: 2
Novel blood biomarkers of human urinary bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 104
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 95
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 92
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 71
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 327
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. The Journal of urology. 2005 Academic Article GET IT
Times cited: 91
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 168
The integration of chemotherapy and surgery for bladder cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2005 Review GET IT
Times cited: 9
Recommendations for a Global Core Curriculum in Medical Oncology. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 36
Recommendations for a global core curriculum in medical oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 33
Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. International journal of cancer. 2004 Academic Article GET IT
Times cited: 47
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2004 Academic Article GET IT
Times cited: 12
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 75
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer immunity. 2003 Academic Article GET IT
Times cited: 67
The phase III candidate: can we improve the science of selection?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 25
Chemotherapy for teratoma with malignant transformation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 175
Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. The Journal of urology. 2003 Academic Article GET IT
Times cited: 47
Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003 Academic Article GET IT
Times cited: 77
Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. The Journal of urology. 2003 Academic Article GET IT
Times cited: 19
Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 21
Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer. 2003 Review GET IT
Times cited: 36
Chemotherapy for good-risk germ-cell tumors. Seminars in urologic oncology. 2002 Review GET IT
Times cited: 3
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 149
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. The Journal of urology. 2002 Academic Article GET IT
Times cited: 521
Salvage chemotherapy for patients with advanced pure seminoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 51
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. International journal of surgical pathology. 2002 Academic Article GET IT
Times cited: 73
Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 17
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 121
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 90
Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. The Journal of urology. 2001 Academic Article GET IT
Times cited: 140
Chemotherapy agents in transitional cell carcinoma: the old and the new. Seminars in urologic oncology. 2001 Review GET IT
Times cited: 3
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 82
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 187
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Investigational new drugs. 2000 Academic Article GET IT
Times cited: 19
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2000 Academic Article GET IT
Times cited: 12
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract. European journal of cancer (Oxford, England : 1990). 2000 Academic Article GET IT
Times cited: 3
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 235
Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy. Radiology. 2000 Academic Article GET IT
Times cited: 29
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 2000 Academic Article GET IT
Times cited: 111
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 165
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 64
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. Cancer investigation. 2000 Academic Article GET IT
Times cited: 9
Paclitaxel in the treatment of advanced urothelial cancer. Oncology (Williston Park, N.Y.). 2000 Review GET IT
Times cited: 14
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 612
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 59
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 149
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Cancer. 1999 Academic Article GET IT
Times cited: 9
Can p53 help select patients with invasive bladder cancer for bladder preservation?. The Journal of urology. 1999 Academic Article GET IT
Times cited: 46
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 68
New chemotherapy regimens for metastatic bladder cancer. Current opinion in urology. 1998 Academic Article GET IT
Times cited: 2
Poor-risk germ cell tumors. Recent developments. The Urologic clinics of North America. 1998 Review GET IT
Times cited: 11
Risk assessment for metastatic testis cancer. The Urologic clinics of North America. 1998 Review GET IT
Times cited: 16
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 83
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 170
Therapy for good risk germ cell tumors. Seminars in oncology. 1998 Review GET IT
Times cited: 9
Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Letter GET IT
Medical and surgical management of pulmonary metastases from germ cell tumors. Chest surgery clinics of North America. 1998 Review GET IT
Times cited: 8
Metastatic germ cell tumors: modeling for response to chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 24
Training resource document for curriculum development in medical oncology. Adopted on February 20, 1997 by the American Society of Clinical Oncology. 1998 GET IT
Times cited: 9
Combined-modality therapy for bladder cancer. Oncology (Williston Park, N.Y.). 1997 Review GET IT
Times cited: 4
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 156
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 163
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 66
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 47
Bleomycin in germ cell tumor therapy: not all regimens are created equal. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Editorial Article GET IT
Times cited: 15
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 336
Surgery for a post-chemotherapy residual mass in seminoma. The Journal of urology. 1997 Review GET IT
Times cited: 137
Germ cell tumors. Current therapy in endocrinology and metabolism. 1997 Review GET IT
Times cited: 1
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. British journal of cancer. 1996 Academic Article GET IT
Times cited: 30
Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. The Journal of urology. 1996 Academic Article GET IT
Times cited: 52
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 81
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 173
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 152
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 19
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 62
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995 Academic Article GET IT
Times cited: 255
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?. International journal of urology : official journal of the Japanese Urological Association. 1995 Review GET IT
Times cited: 33
Paclitaxel in germ cell cancer. Seminars in oncology. 1995 Review GET IT
Times cited: 26
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 239
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 208
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. The Journal of urology. 1995 Review GET IT
Times cited: 67
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 1995 Academic Article GET IT
Times cited: 28
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 30
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 186
The management of patients with advanced germ cell tumors. Seminoma and nonseminoma. The Urologic clinics of North America. 1994 Review GET IT
Times cited: 8
Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison. Seminars in oncology. 1994 Academic Article GET IT
Times cited: 13
Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994 Academic Article GET IT
Times cited: 93
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 141
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer. 1994 Academic Article GET IT
Times cited: 65
Bladder cancer: advances in biology and treatment. Critical reviews in oncology/hematology. 1994 Review GET IT
Times cited: 8
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 138
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Archives of otolaryngology--head & neck surgery. 1994 Academic Article GET IT
Times cited: 35
Germ cell tumors. Current therapy in endocrinology and metabolism. 1994 Academic Article GET IT
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer. 1993 Academic Article GET IT
Times cited: 19
Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 148
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993 Academic Article GET IT
Times cited: 218
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 306
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 100
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Investigational new drugs. 1993 Academic Article GET IT
Times cited: 4
Management of the postchemotherapy residual mass. The Urologic clinics of North America. 1993 Review GET IT
Times cited: 35
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 112
The evolving role of chemotherapy of germ cell tumors. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1993 Review GET IT
Times cited: 1
Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Seminars in oncology. 1992 Academic Article GET IT
Times cited: 29
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma research. 1992 Academic Article GET IT
Times cited: 41
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer research. 1992 Academic Article GET IT
Times cited: 49
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 70
"Poor-risk" germ cell tumors: current progress and future directions. Seminars in oncology. 1992 Review GET IT
Times cited: 26
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Seminars in oncology. 1992 Review GET IT
Times cited: 60
Immunotherapy with monoclonal antibodies in metastatic melanoma. World journal of surgery. 1992 Review GET IT
Times cited: 20
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer. 1991 Academic Article GET IT
Times cited: 89
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer. 1991 Academic Article GET IT
Times cited: 29
Macrophage colony-stimulating factor: biological effects and potential applications for cancer therapy. Seminars in hematology. 1991 Review GET IT
Times cited: 18
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. 1991 GET IT
Times cited: 64
Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. Cancer. 1991 Academic Article GET IT
Times cited: 20
Phase II trial of N-methylformamide in patients with metastatic melanoma. Investigational new drugs. 1991 Academic Article GET IT
Times cited: 4
Phase II trial of cisplatin and etoposide in patients with metastatic melanoma. Investigational new drugs. 1991 Academic Article GET IT
Times cited: 2
Assessment of risk in metastatic testis carcinoma: impact on treatment. Urologia internationalis. 1991 Review GET IT
Times cited: 4
Continued refinement in the treatment of germ cell tumour patients. European journal of cancer (Oxford, England : 1990). 1991 Editorial Article GET IT
Times cited: 2
Haemodynamic effects of recombinant interleukin-2 administered by constant infusion. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 4
Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. Journal of cancer research and clinical oncology. 1991 Academic Article GET IT
Times cited: 35
Two-drug therapy in patients with metastatic germ cell tumors. Cancer. 1991 Academic Article GET IT
Times cited: 29
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer. 1990 Academic Article GET IT
Times cited: 112
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer research. 1990 Academic Article GET IT
Times cited: 83
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Investigational new drugs. 1990 Academic Article GET IT
Times cited: 14
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Academic Article GET IT
Times cited: 253
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer. 1990 Academic Article GET IT
Times cited: 31
Decompression of epidural metastases from germ cell tumors with chemotherapy. 1990 GET IT
Times cited: 27
Phase II trial of carboplatin in patients with advanced melanoma. Investigational new drugs. 1990 Academic Article GET IT
Times cited: 17
A phase I trial of combination chemotherapy employing carboplatin, vinca alkaloids, with or without bleomycin in patients with advanced malignant tumors. Cancer investigation. 1990 Academic Article GET IT
Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside. Progress in clinical and biological research. 1989 Academic Article GET IT
Times cited: 9
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 216
Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Seminars in oncology. 1988 Academic Article GET IT
Times cited: 25
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 113
Phase I trial of escalating doses of cisplatin in hypertonic saline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 Academic Article GET IT
Times cited: 30
Phase II trial of mitomycin in malignant mesothelioma. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 45
An analysis of poor risk assignment in patients with germ cell tumours. International journal of andrology. 1987 Academic Article GET IT
Times cited: 1
Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer research. 1986 Academic Article GET IT
Times cited: 37
Phase II trial of dichloromethotrexate in epidermoid carcinoma of the esophagus. Cancer treatment reports. 1986 Academic Article GET IT
Times cited: 4

more ...

less ...

Background

education and training

M.D., New York Medical College 1978
B.A., College of the Holy Cross 1973

Contact

full name

Dean F. Bajorin

VIVO Weill Cornell Medical College

Dean F. Bajorin Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name